GIUV2014-200
At the beginning, our group was dedicated to the study and characterisation of gastrointestinal disorders related to acid production and motility, becoming an international reference group in this field due to the large number of high-level publications in the area of basic or experimental pharmacology. New applications for the study of drug effects, such as genetics or molecular biology, have led to a broadening of the topics to be studied. The most important characteristic of our group from a research point of view is the desire for our different lines of research to be focused on the study of physiological and pathological processes with a broad clinical impact. That is why our lines of research address diseases of particular relevance in today's society: Crohn's disease, NSAID gastroenteropathy, AIDS, diabetes and obesity. Since its foundation in 2007, our group has been part of the Centro de Investigación Biomédica en Red: Liver and Digestive Diseases (CIBERehd), whose function is to promote research of excellence at both clinical and basic levels. In addition, we have been recognised by the Valencian Government as a group of excellence within the PROMETEO 2010 call. Our...At the beginning, our group was dedicated to the study and characterisation of gastrointestinal disorders related to acid production and motility, becoming an international reference group in this field due to the large number of high-level publications in the area of basic or experimental pharmacology. New applications for the study of drug effects, such as genetics or molecular biology, have led to a broadening of the topics to be studied. The most important characteristic of our group from a research point of view is the desire for our different lines of research to be focused on the study of physiological and pathological processes with a broad clinical impact. That is why our lines of research address diseases of particular relevance in today's society: Crohn's disease, NSAID gastroenteropathy, AIDS, diabetes and obesity. Since its foundation in 2007, our group has been part of the Centro de Investigación Biomédica en Red: Liver and Digestive Diseases (CIBERehd), whose function is to promote research of excellence at both clinical and basic levels. In addition, we have been recognised by the Valencian Government as a group of excellence within the PROMETEO 2010 call. Our group has published more than 200 articles and reviews in international journals including, among others, Gastroenterology, Hepatology, PNAS, Circulation, Immunity, Circulation Research, British Journal of Pharmacology and Trends in Pharmacological Sciences.
[Read more][Hide]
[Read more][Hide]
- Esclarecer los mecanismos fisiopatologicos de las enfermedades cronicas mencionadas anteriormente y optimizar el tratamiento de las mismas.
- Modulation of autophagy in epithelial cells by macrophages: relevance in Crohn¿s Disease and in non-steroidal anti-inflammatory drug-induced gastroent.We study the mechanisms that regulate gastrointestinal mucosal recovery in chronic inflammatory pathologies (e. g. IBD), in particular how macrophages, cells of the innate immune system that accumulate in the mucosa of patients with this pathology, modulate these mechanisms.
- Study of the cellular and molecular mechanisms involved in the vascular toxicity induced by antiretroviral therapy..We study the mechanisms responsible for the vascular toxicity described for some antiretroviral drugs. We have analysed the effect of the most commonly used antiretroviral drugs on leukocyte-endothelium interaction as a first step in the development of vascular pathologies.
- Characterisation of cellular mechanisms of toxicity induced by antiretroviral drugs..We study the mechanisms responsible for the toxicity of antiretroviral therapy in different organs and tissues, with special emphasis on three of the main adverse effects associated with this treatment: liver toxicity, metabolic alterations and neurotoxicity.
- Mitochondrial-endothelial dysfunction, reticulum stress and autophagy in type 2 diabetes: physiolopathological and therapeutic implications..We studied type 2 diabetes and mitochondrial dysfunction, having shown that it correlates with the development of silent ischaemic heart disease. We have also shown that high levels of myeloperoxidase correlate with the development of diabetic nephropathy in type 2 diabetes.
| Name | Nature of participation | Entity | Description |
|---|---|---|---|
| JUAN VICENTE ESPLUGUES MOTA | Director | Universitat de València | |
| Research team | |||
| MIGUEL MARTI CABRERA | Member | Universitat de València | |
| ANGELES ALVAREZ RIBELLES | Member | Universitat de València | |
| MARIA ANGELES MARTINEZ CUESTA | Member | Universitat de València | |
| MARIA DOLORES BARRACHINA SANCHO | Member | Universitat de València | |
| FRANCISCA SARA CALATAYUD ROMERO | Member | Universitat de València | |
| MARIA DOLORES ORTIZ MASIA | Member | Universitat de València | |
| ANA BLAS GARCIA | Member | Universitat de València | |
| JOAQUIN E HINOJOSA DEL VAL | Collaborator | Hospital de Manisses | doctor |
| CARLOS HERNANDEZ SAEZ | Collaborator | Fundacion para el Fomento de la Investigacion Sanitaria y Biomedica de la Comunitat Valenciana (FISABIO) | researcher |
| MARIA JOSE GALINDO PUERTO | Collaborator | Universitat de València | |
| NADEZDA APOSTOLOVA ATANASOVSKA | Collaborator | Universitat de València | |
| FERNANDO ALEGRE GUERRA | Collaborator | Fundacion para el Fomento de la Investigacion Sanitaria y Biomedica de la Comunitat Valenciana (FISABIO) | trainee research staff |
| MIRIAM POLO PEÑALVER | Collaborator | Fundacion para el Fomento de la Investigacion Sanitaria y Biomedica de la Comunitat Valenciana (FISABIO) | trainee research staff |
| CESAR RIOS NAVARRO | Collaborator | Universitat de València | |
| CESAR RIOS NAVARRO | Collaborator | Fundacion para el Fomento de la Investigacion Sanitaria y Biomedica de la Comunitat Valenciana (FISABIO) | trainee research staff |
| MARÍA MILAGROS ROCHA BARAJAS | Collaborator | Fundacion para el Fomento de la Investigacion Sanitaria y Biomedica de la Comunitat Valenciana (FISABIO) | researcher |
| VICTOR MANUEL VICTOR GONZALEZ | Collaborator | Universitat de València | |
| AMELIA GONZALEZ RAMON | Collaborator | Fundacion para el Fomento de la Investigacion Sanitaria y Biomedica de la Comunitat Valenciana (FISABIO) | technical officer |
| BRIAN JAMES NORMANLY - | Collaborator | Centro de Investigación Biomédica en Red del Área Temática de Enfermedades Hepáticas y Digestivas | technical officer |
| RAFAEL ALOS COMPANY | Collaborator | Hospital de Manisses | doctor |
| MARTA MONTERO ALONSO | Collaborator | Universitat de València | |
| MARTA MONTERO ALONSO | Collaborator | Hospital Universitari i Politècnic La Fe | doctor |
| NICOLE ROUPAIN | Collaborator | Fundacion para el Fomento de la Investigacion Sanitaria y Biomedica de la Comunitat Valenciana (FISABIO) | trainee research staff |
- -
- Pharmacology
- inflamación, función barrera-epitelial, enfermedad de Chron, colitis ulcerosa, inmunidad innata
- Antirretroviral, toxicidad vascular, interacción leucocito-endotelio, plaqueta, moléculas de adhesión.
- hepatotoxicidad, antirretrovirales, mitocondria, VIH, neurotoxicidad, bioenergética
- Diabetes tipo 2, mitocondria, endotelio, enfermedad cardiometabólica, humanos
